

Cover Story
News Analysis
For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - ACOG says it will no longer accept federal funding
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- The Med Student’s Memo – Research Concerns
- ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV